Sildenafil (Viagra®) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model

Cytokine

Volumn 60, Issue 2, 2012, Pages 540-551

  Nunes, Ana Karolina de Santana ^a,b   Rapôso, Catarina ^a,c   Luna, Rayana Leal de Almeida ^b   Cruz Höfling, Maria Alice da ^c   Peixoto, Christina Alves ^a,b  

^a Laboratory of Nanomaterials LMNano2   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Astrocytes; Cerebellum; CGMP; Microglia; Nitric oxide

Indexed keywords

CARRIER PROTEIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; PROTEIN IBA 1; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ULTRASTRUCTURE; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE INJURY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; CEREBELLUM; CUPRIZONE; CYCLOOXYGENASE 2; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; PIPERAZINES; PURINES; SULFONES;

ANIMALIA; EPICOCCUM; MUS; RODENTIA;

EID: 84866770267     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.011     Document Type: Article

References (67)

1. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
2. McGeer E.G., McGeer P.L. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 2007, 21:789-797.
3. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
4. Moharregh-Khiabani D., Blank A., Skripuletz T., Miller E., Kotsiari A., Gudi V., et al. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS One 2010, 5:117-169.
5. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. New Engl J Med 2000, 343:938-952.
6. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transaction in the lesions of multiple sclerosis. New Engl J Med 1998, 338:278-285.
7. Gao Z., Tsirka S.E. Animal Models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol Res Int 2011, 2011:383087.
8. Kipp M., Norkus A., Krauspe B., Clarner T., Berger K., van der Valk P., et al. The hippocampal fimbria of cuprizone-treated animals as a structure for studying neuroprotection in multiple sclerosis. Inflamm Res 2011, 60:723-726.
9. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener 2009, 4:47.
10. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26:349-354.
11. Johnson K.P., Brooks B.R., Ford C.C., Goodman A., Guarnaccia J., Lisak R.P., et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000, 6:255-266.
12. Reder A.T., Ebers G.C., Traboulsee A., Li D., Langdon D., Goodin D.S., et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 2010, 74:1877-1885.
13. Yoshioka A., Yamaya Y., Saiki S., Kanemoto M., Hirose G., Pleasure D. Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell line. J Neurochem 2000, 74:633-640.
14. Huizinga R., van der Star B.J., Kipp M., Jong R., Gerritsen W., Clarner T., et al. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia 2012, 60:422-431.
15. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., et al. Activation of microglial cells by ß-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
16. Pifarré P., Prado J., Baltrons M.A., Giralt M., Gabarro P., Feinstein D.L., et al. Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol 2011, 121:499-508.
17. Rosenberg G.A. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012, 10.1038/jcbfm.2011.197.
18. Puzzo D., Sapienza S., Arancio O., Palmeri A. Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 2008, 4:371-387.
19. Prickaerts J., van Staveren W.C., Sik A., Markerink-van Ittersum M., Niewöhner U., van der Staay F.J., et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002, 113:351-361.
20. Boccia M.M. CM. Effects of oxytocin and an oxytocin receptor antagonist on retention of a nose-poke habituation response in mice. Acta Physiol Pharmacol Ther Latinoam 1999, 49:155-160.
21. Wakita H., Tomimoto H., Akiguchi I., Lin J.X., Ihara M., Ohtani R., et al. Ibudilast protect against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res 2003, 992:53-59.
22. Manson SC, Burke G, Voets N, Palace J, Matthews PM. Effect of sildenafil citrate on CBF and BOLD activation in multiple sclerosis patients. 21st congress of the European Committee for the Treatment and Research in Multiple Sclerosis 2005; Poster No. 237 Thessaloniki, Greece.
23. Zhang L., Yu W., Schroedter I., Kong J., Vrontakis M. Galanin transgenic mice with elevated circulating galanin levels alleviate demyelination in a cuprizone-induced MS mouse model. PLoS One 2012, 7:e33901.
24. Silvestroff L., Bartucci S., Pasquini J., Franco P. Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol 2012, 10.1016/j.expneurol.2012.02.01.
25. Zhao L., Mason N.A., Strange J.W., Walker H., Wilkins M.R. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 2003, 107:234-237.
26. Saraiva K.L., Silva A.K., Wanderley M.I., De Araújo A.A., De Souza J.R., Peixoto C.A. Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. Int J Exp Pathol 2009, 90:454-462.
27. Saraiva K.L., Silva V.A., Dias E.S., Peixoto C.A. Morphological changes in the testis induced by diethylcarbamazine. Reprod Toxicol 2006, 22:754-759.
28. Riccitelli G., Rocca M.A., Pagani E., Martinelli V., Radaelli M., Falini A., et al. Mapping regional grey and white matter atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2012, 10.1177/1352458512439239.
29. Shields S.D., Cheng X., Gasser A., Saab C.Y., Tyrrell L., Eastman E.M., et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 2012, 71:186-194.
30. Skripuletz T., Bussmann J.H., Gudi V., Koutsoudaki P.N., Pul R., Moharregh-Khiabani D., et al. Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol 2010, 20:301-312.
31. Zhang R.L., Zhang Z., Zhang L., Wang Y., Zhang C., Chopp M. Delayed treatment with Sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 2006, 83:1213-1219.
32. Zhang Y.Q., Rodesch C.K., Broadie K. Living synaptic vesicle marker: synaptotagmin-GFP. Genesis 2002, 34:142-145.
33. Kulkarni S.K., Patil C.S. Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 2004, 26:789-799.
34. Shimizu-Albergine M., Rybalkin S.D., Rybalkina I.G., Feil R., Wolfsgruber W., Hofmann F., et al. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 2003, 23:6452-6459.
35. Rosengren L.E., Lycke J., Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995, 133:61-65.
36. Petzold A., Eikelenboom M.J., Gyeric D., et al. Markers for differential glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002, 125:1462-1473.
37. Tani M., Glabinski A.R., Tuohy V.K., Stoler M.H., Estes M.L., Ransohoff R.M. In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am J Pathol 1996, 148:889-896.
38. Voskuhi R.R., Peterson R.S., Song B., Ao Y., Morales L.B., Tiwari-Woodruff S., et al. Reactive astrocytes form scar-like perivascular barriers to leukocutes during adaptative immune inflammation of the CNS. J Neurosci 2009, 29:11511-11522.
39. Glabinski A.R., Tani M., Strieter R.M., Tuohy V.K., Ransohoff R.M. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997, 150:617-630.
40. Ambrosini E., Remoli M.E., Giacomini E., Rosicarelli B., Serafini B., Lande R., et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 2005, 64:706-715.
41. Hardin-Pouzet H., Krakowski M., Bourbonnière L., Didier-Bazes M., Tran E., Owens T. Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 1997, 20:79-85.
42. Korn T., Magnus T., Jung S. Autoantigen specific T cells inhibit glutamate uptake in astrocytes by decreasing expression of astrocytic glutamate transporter GlAST: a mechanism mediated by tumor necrosis factor-alpha. FASEB J 2005, 19:1878-1880.
43. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000, 6:67-70.
44. Micu J., Jiang Q., Coderre E., Ridsdale A., Zhang L., Woulfe J., et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006, 439:988-992.
45. Back S.A., Tuohy T.M., Chen H., Wallingford N., Craig A., Struve J., et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005, 11(9):966-972. Epub 2005 August 7.
46. Toft-Hansen H., Füchtbauer L., Owens T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia 2011, 59:166-176.
47. Bannerman P., Hahn A., Soulika A., Gallo V., Pleasure D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 2007, 55:57-64.
48. Pifarré P., Prado J., Giralt M., Molinero A., Hidalgo J., Garcia A. Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury. J Neurochem 2010, 112:807-817.
49. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994, 24:1434-1440.
50. Stevens D.B., Gould K.E., Swanborg R.H. Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J Neuroimmunol 1994, 51:77-83.
51. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
52. Khoshakhlagh P., Bahrololoumi-Shapourabadi M., Mohammadirad A., Ashtaral-Nakhai L., Minaie B., Abdollahi M. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007, 17(5):281-288.
53. Suzumura A., Ito A., Yoshikawa M., Sawada M. Ibudilast suppressesTNF alpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 1999, 837:203-212.
54. da Cruz-Höfling M.A., Rapôso C., Verinaud L., Zago G.M. Neuroinflammation and astrocytic reaction in the course of Phoneutria nigriventer (armed-spider) blood-brain barrier (BBB) opening. Neurotoxicology 2009, 30:636-646.
55. Palumbo M.L., Trinchero M.F., Zorrilla-Zubilete M.A., Schinder A.F., Genaro A.M. Glatiramer acetate reverts stress-induced alterations on adult neurogenesis and behavior. Involvement of Th1/Th2 balance. Behav Brain Res 2011, 218:121-128.
56. Zhao S., Zhang L., Lian G., Wang X., Zhang H., Yao X., et al. Sildenafil attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-κB signaling pathways in N9 microglia. Int Immunopharmacol 2011, 11:468-474.
57. Wang L., Chopp M., Szalad A., Liu Z., Bolz M., Alvarez F.M., et al. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience 2011, 193:399-410.
58. Benjamins J.A., Nedelkoska L. Cyclic GMP-dependent pathways protect differentiated oligodendrocytes from multiple types of injury. Neurochem Res 2007, 32:321-329.
59. Wang X., Robinson P.J. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem 1997, 68:443-456.
60. Abramovitz M., Adam M., Boie Y., et al. Theutilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000, 1483:285-293.
61. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 2004, 56:240-248.
62. Carlson N.G., Rojas M.A., Black J.D., Redd J.W., Hille J., Hill K.E., et al. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation 2009, 6:5.
63. Farooqui A.A., Horrocks L.A., Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 2007, 101:577-599.
64. Dore-Duffy P., Donaldson J.O., Koff T., Longo M., Perry W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 1986, 36:1587-1590.
65. Neu I.S., Metzger G., Zschocke J., Zelezny R., Mayatepek E. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol Scand 2002, 105:63-66.
66. Dore-Duffy P., Ho S.Y., Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 1991, 41:322-324.
67. Muthian G., Raikwar H.P., Johnson C., Rajasingh J., Kalgutkar A., Marnett L.J., et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 2006, 26:73-85.